Hematopoietic Stem Cell Transplantation Market Report 2026

The hematopoietic stem cell transplantation market size has grown rapidly in recent years. It will grow from $5.1 billion in 2025 to $5.64 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to increasing prevalence of hematologic disorders, expansion of transplant centers, improved donor matching techniques, rising use of autologous transplants, advancements in supportive care protocols.

The hematopoietic stem cell transplantation market size is expected to see rapid growth in the next few years. It will grow to $8.57 billion in 2030 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to increasing adoption of gene-modified stem cell therapies, rising investments in transplant infrastructure, expansion of allogeneic transplant procedures, growing focus on personalized transplant approaches, increasing survival rates post-transplant. Major trends in the forecast period include increasing adoption of peripheral blood stem cell transplants, rising use of cord blood transplantation, growing integration of precision conditioning regimens, expansion of donor registry networks, enhanced focus on post-transplant monitoring.

The rising incidence of blood cancers is expected to drive the growth of the hematopoietic stem cell transplantation market going forward. Blood cancers are a group of malignancies that affect the formation and function of blood cells, with leukemia, lymphoma, and myeloma being the primary types. Hematopoietic stem cell transplantation is commonly used to treat blood cancers by replacing stem cells and bone marrow cells destroyed by the disease. These transplanted stem cells migrate to the bone marrow and begin producing new, healthy blood cells, supporting recovery and disease management. Consequently, these factors contribute to the expansion of the hematopoietic stem cell transplantation market. For instance, in September 2025, according to Cancer Research UK, a UK-based charity, the incidence rate of leukemia in the UK from 2024 to 2026 is estimated at about 17.9 cases per 100,000 people annually and is projected to decline by 3% to approximately 17.4 cases per 100,000 between 2038 and 2040. Therefore, the increasing frequency of blood cancer is driving the growth of the hematopoietic stem cell transplantation market.

Companies operating in the hematopoietic stem cell transplantation market are increasingly focusing on developing innovations such as digital resources to streamline patient management, improve donor matching processes, and deliver real-time data analytics to support better clinical decision-making. Digital resources include online tools, platforms, or materials that provide information, services, or functionality in a digital format. For example, in September 2024, BioLineRx Ltd., an Israel-based biopharmaceutical company, launched Mobilization Matters, a digital resource. Mobilization Matters is an interactive platform designed to educate healthcare professionals and patients about stem cell mobilization for transplantation. It provides detailed guidelines, best practices, and real-time tracking tools to optimize stem cell collection, thereby improving patient outcomes and ensuring efficient resource utilization in transplantation procedures.

In June 2024, BlueSphere Bio, a US-based biotechnology company, entered into a partnership with NMDP BioTherapies to advance its first-in-human TCR-based product candidate in combination with allogeneic hematopoietic cell transplantation. Through this collaboration, the companies aim to assess the safety and effectiveness of the novel therapy, accelerate its clinical development, and broaden treatment options for patients with hematologic malignancies, while supporting innovation within the cell and gene therapy market. NMDP BioTherapies is a US-based nonprofit organization focused on the development and manufacturing of cellular therapies for transplantation and immunotherapy applications.

Major companies operating in the hematopoietic stem cell transplantation market are Pluristem Therapeutics Inc., Lonza Group AG, Escape Therapeutics Inc., Regen Biopharma Inc., Bluebird Bio Inc., CellGenix GmbH, CBR Systems Inc., Merck KGaA, Cord Blood Corporation, Kiadis Pharma NV, Marker Therapeutics Inc., Taiga Biotechnologies Inc., Takeda Pharmaceutical Company Limited, Talaris Therapeutics Inc., ViaCord LLC, ScienCell Research Laboratories Inc., BiolineRx, Stemcell Technologies Inc., ThermoGenesis Holdings Inc., MEDIPOST Co. Ltd., Anterogen. Co. Ltd., Pharmicell Inc., JCR Pharmaceuticals Co. Ltd., Holostem Terapie Avanzate Srl, Regrow Biosciences Pvt Ltd., Stempeutics Research Pvt Ltd.

North America was the largest region in the hematopoietic stem cell transplantation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global hematopoietic stem cell transplantation market during the forecast period. The regions covered in the hematopoietic stem cell transplantation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hematopoietic stem cell transplantation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the hematopoietic stem cell transplantation market by increasing costs of imported cell processing equipment, cryopreservation systems, reagents, and laboratory consumables. Transplant centers in North America and Europe are most affected due to dependence on specialized imported technologies, while Asia-Pacific faces higher costs for expanding transplant infrastructure. These tariffs are increasing procedural costs and slowing capacity expansion. At the same time, they are encouraging local manufacturing of transplant consumables, regional processing facilities, and domestic capability development in stem cell handling technologies.

The hematopoietic stem cell transplantation market research report is one of a series of new reports that provides hematopoietic stem cell transplantation market statistics, including hematopoietic stem cell transplantation industry global market size, regional shares, competitors with a hematopoietic stem cell transplantation market share, detailed hematopoietic stem cell transplantation market segments, market trends and opportunities, and any further data you may need to thrive in the hematopoietic stem cell transplantation industry. This hematopoietic stem cell transplantation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hematopoietic stem cell transplantation (HSCT) is a medical procedure used to treat a range of blood and bone marrow disorders, including certain genetic conditions and autoimmune diseases. The procedure involves replacing a patient’s damaged or diseased bone marrow with healthy stem cells from a donor, which then engraft and generate new blood cells in the patient’s body. These stem cells can be sourced from bone marrow, peripheral blood, or umbilical cord blood.

The primary cell types used in hematopoietic stem cell transplantation are allogeneic and autologous. Allogeneic transplantation refers to a stem cell transplant in which the donor and recipient are different individuals with distinct genetic profiles. It is used to treat various indications such as leukemia, lymphatic disorders, myeloma, and others, and is applied across procedures including bone marrow transplants, peripheral blood stem cell transplants, and cord blood transplants. The main end users include hospital pharmacies, retail pharmacies, and specialty clinics.

The hematopoietic stem cell transplantation (HSCT) market includes revenues earned by entities providing services such as medical evaluation, pre-transplant care, stem cell collection and processing, transplantation procedures, post-transplant care, supportive care, and long-term follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.